Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

NOP receptor pharmacological profile - A dynamic mass redistribution study.

Malfacini D, Simon K, Trapella C, Guerrini R, Zaveri NT, Kostenis E, Calo' G.

PLoS One. 2018 Aug 30;13(8):e0203021. doi: 10.1371/journal.pone.0203021. eCollection 2018.

2.

A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC.

Sci Transl Med. 2018 Aug 29;10(456). pii: eaar3483. doi: 10.1126/scitranslmed.aar3483.

PMID:
30158150
3.

Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.

Silva EF, Silva AI, Asth L, Souza LS, Zaveri NT, Guerrini R, Calo' G, Ruzza C, Gavioli EC.

Behav Brain Res. 2018 Aug 22;356:120-126. doi: 10.1016/j.bbr.2018.08.019. [Epub ahead of print]

PMID:
30142397
4.

Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs.

Cippitelli A, Brunori G, Schoch J, Armishaw CJ, Wu J, Zaveri NT, Giulianotti MA, Welmaker GS, Toll L.

Psychopharmacology (Berl). 2018 Jun;235(6):1745-1757. doi: 10.1007/s00213-018-4883-y. Epub 2018 Mar 23.

PMID:
29572652
5.

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M.

Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31.

PMID:
29232769
6.

A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Zaveri NT, Marquez PV, Meyer ME, Polgar WE, Hamid A, Lutfy K.

Alcohol Clin Exp Res. 2018 Feb;42(2):461-471. doi: 10.1111/acer.13575. Epub 2018 Jan 19.

7.

Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.

Journigan VB, Polgar WE, Tuan EW, Lu J, Daga PR, Zaveri NT.

Sci Rep. 2017 Oct 16;7(1):13255. doi: 10.1038/s41598-017-13129-1.

8.

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT.

Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.333.

9.

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.

Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L.

Neuropharmacology. 2017 Oct;125:39-49. doi: 10.1016/j.neuropharm.2017.07.006. Epub 2017 Jul 10.

PMID:
28705439
10.

The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.

Yuan M, Malagon AM, Yasuda D, Belluzzi JD, Leslie FM, Zaveri NT.

Behav Brain Res. 2017 Aug 30;333:251-257. doi: 10.1016/j.bbr.2017.07.004. Epub 2017 Jul 8.

11.

Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan VB, Zaveri NT, Ciccocioppo R.

Addict Biol. 2018 Mar;23(2):585-595. doi: 10.1111/adb.12513. Epub 2017 Jun 21.

12.

In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G.

Eur J Pharmacol. 2016 Dec 15;793:1-13. doi: 10.1016/j.ejphar.2016.10.025. Epub 2016 Oct 22.

13.

A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration.

Cippitelli A, Schoch J, Debevec G, Brunori G, Zaveri NT, Toll L.

Sci Rep. 2016 May 20;6:26594. doi: 10.1038/srep26594.

14.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

15.

Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Zaveri NT.

J Med Chem. 2016 Aug 11;59(15):7011-28. doi: 10.1021/acs.jmedchem.5b01499. Epub 2016 Mar 14. Review.

16.

Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.

Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G.

Neuropharmacology. 2016 Jun;105:434-442. doi: 10.1016/j.neuropharm.2016.02.003. Epub 2016 Feb 8.

17.

The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

Lutfy K, Zaveri NT.

Prog Mol Biol Transl Sci. 2016;137:149-81. doi: 10.1016/bs.pmbts.2015.10.003. Epub 2015 Dec 23. Review.

18.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

19.

Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.

Vang D, Paul JA, Nguyen J, Tran H, Vincent L, Yasuda D, Zaveri NT, Gupta K.

Haematologica. 2015 Dec;100(12):1517-25. doi: 10.3324/haematol.2015.128736. Epub 2015 Aug 20.

20.

Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization.

Ozawa A, Brunori G, Mercatelli D, Wu J, Cippitelli A, Zou B, Xie XS, Williams M, Zaveri NT, Low S, Scherrer G, Kieffer BL, Toll L.

J Neurosci. 2015 Aug 19;35(33):11682-93. doi: 10.1523/JNEUROSCI.5122-14.2015.

21.

High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice.

Khroyan TV, Yasuda D, Toll L, Polgar WE, Zaveri NT.

Biochem Pharmacol. 2015 Oct 15;97(4):531-541. doi: 10.1016/j.bcp.2015.08.083. Epub 2015 Aug 7.

22.

Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001.

Cippitelli A, Brunori G, Gaiolini KA, Zaveri NT, Toll L.

Neuropharmacology. 2015 Jun;93:229-36. doi: 10.1016/j.neuropharm.2015.02.005. Epub 2015 Feb 14.

23.

Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.

Zaveri NT, Journigan VB, Polgar WE.

ACS Chem Neurosci. 2015 Apr 15;6(4):646-57. doi: 10.1021/cn500367b. Epub 2015 Feb 18.

24.

AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.

Cippitelli A, Wu J, Gaiolini KA, Mercatelli D, Schoch J, Gorman M, Ramirez A, Ciccocioppo R, Khroyan TV, Yasuda D, Zaveri NT, Pascual C, Xie XS, Toll L.

Br J Pharmacol. 2015 Apr;172(7):1834-45. doi: 10.1111/bph.13034. Epub 2015 Jan 23.

25.

Functional characterization of AT-1001, an α3β4 nicotinic acetylcholine receptor ligand, at human α3β4 and α4β2 nAChR.

Zaveri NT, Bertrand S, Yasuda D, Bertrand D.

Nicotine Tob Res. 2015 Mar;17(3):361-7. doi: 10.1093/ntr/ntu170. Epub 2014 Sep 1.

26.

Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.

Daga PR, Polgar WE, Zaveri NT.

J Chem Inf Model. 2014 Oct 27;54(10):2732-43. doi: 10.1021/ci500291a. Epub 2014 Sep 17.

27.

The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Muldoon PP, Jackson KJ, Perez E, Harenza JL, Molas S, Rais B, Anwar H, Zaveri NT, Maldonado R, Maskos U, McIntosh JM, Dierssen M, Miles MF, Chen X, De Biasi M, Damaj MI.

Br J Pharmacol. 2014 Aug;171(16):3845-57. doi: 10.1111/bph.12741.

28.

Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.

Journigan VB, Polgar WE, Khroyan TV, Zaveri NT.

Bioorg Med Chem. 2014 Apr 15;22(8):2508-16. doi: 10.1016/j.bmc.2014.02.047. Epub 2014 Mar 5.

29.

Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats.

Costello MR, Reynaga DD, Mojica CY, Zaveri NT, Belluzzi JD, Leslie FM.

Neuropsychopharmacology. 2014 Jul;39(8):1843-51. doi: 10.1038/npp.2014.31. Epub 2014 Feb 11.

30.

[¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Wu J, Perry DC, Bupp JE, Jiang F, Polgar WE, Toll L, Zaveri NT.

Neuropharmacology. 2014 Feb;77:193-9. doi: 10.1016/j.neuropharm.2013.09.023. Epub 2013 Oct 3.

31.

Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC.

J Pharmacol Exp Ther. 2013 Jul;346(1):11-22. doi: 10.1124/jpet.113.203984. Epub 2013 May 7.

32.

Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.

Zaveri NT, Jiang F, Olsen C, Polgar WE, Toll L.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3308-13. doi: 10.1016/j.bmcl.2013.03.101. Epub 2013 Apr 4.

33.

Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activity.

Vazquez-DeRose J, Stauber G, Khroyan TV, Xie XS, Zaveri NT, Toll L.

Eur J Pharmacol. 2013 Jan 15;699(1-3):200-6. doi: 10.1016/j.ejphar.2012.11.050. Epub 2012 Dec 5.

34.

TRPM8 ion channel ligands for new therapeutic applications and as probes to study menthol pharmacology.

Journigan VB, Zaveri NT.

Life Sci. 2013 Mar 19;92(8-9):425-37. doi: 10.1016/j.lfs.2012.10.032. Epub 2012 Nov 16. Review.

PMID:
23159643
35.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.

Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x.

36.

Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™.

Khroyan TV, Zhang J, Yang L, Zou B, Xie J, Pascual C, Malik A, Xie J, Zaveri NT, Vazquez J, Polgar W, Toll L, Fang J, Xie X.

Clin Exp Pharmacol Physiol. 2012 Jul;39(7):614-22. doi: 10.1111/j.1440-1681.2012.05719.x.

37.
38.

AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello MR, Leslie FM.

Neuropsychopharmacology. 2012 May;37(6):1367-76. doi: 10.1038/npp.2011.322. Epub 2012 Jan 25.

39.

Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.

Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2011 Nov;339(2):687-93. doi: 10.1124/jpet.111.184663. Epub 2011 Aug 22.

40.

Orphanin FQ/nociceptin activates nuclear factor kappa B.

Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM.

J Neuroimmune Pharmacol. 2011 Dec;6(4):617-25. doi: 10.1007/s11481-011-9279-2. Epub 2011 May 6.

42.
43.

Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT.

J Pharmacol Exp Ther. 2009 Dec;331(3):954-64. doi: 10.1124/jpet.109.157446. Epub 2009 Sep 22.

44.

Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179.

Waleh NS, Murphy BJ, Zaveri NT.

Cancer Lett. 2010 Mar 1;289(1):111-8. doi: 10.1016/j.canlet.2009.08.006. Epub 2009 Sep 13.

PMID:
19751965
45.

Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2009 Dec;331(3):946-53. doi: 10.1124/jpet.109.156711. Epub 2009 Aug 27.

46.

A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells.

Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, Murphy BJ.

Cancer Biol Ther. 2009 Jul;8(13):1252-61. Epub 2009 Jul 7.

PMID:
19633434
47.

Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.

Khroyan TV, Polgar WE, Orduna J, Jiang F, Olsen C, Toll L, Zaveri NT.

Eur J Pharmacol. 2009 May 21;610(1-3):49-54. doi: 10.1016/j.ejphar.2009.03.019. Epub 2009 Mar 12.

48.

Evolutionary sequence modeling for discovery of peptide hormones.

Sonmez K, Zaveri NT, Kerman IA, Burke S, Neal CR, Xie X, Watson SJ, Toll L.

PLoS Comput Biol. 2009 Jan;5(1):e1000258. doi: 10.1371/journal.pcbi.1000258. Epub 2009 Jan 9.

49.

Activities of mixed NOP and mu-opioid receptor ligands.

Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, Zaveri NT.

Br J Pharmacol. 2008 Feb;153(3):609-19. Epub 2007 Dec 3.

50.

Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents.

Khroyan TV, Polgar WE, Orduna J, Zaveri NT, Judd AK, Tuttle DJ, Sanchez A, Toll L.

Eur J Pharmacol. 2007 Mar 29;560(1):29-35. Epub 2007 Jan 17.

PMID:
17303110

Supplemental Content

Loading ...
Support Center